Developer docs
API playgroundTry for free, no card

Search company profiles

Creoptix

Full company profile

uuid0003knv

Namestring
Creoptix
Legal namestring
Creoptix (Malvern Panalytical brand)
Websiteurl
creoptix.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Creoptix is a Swiss-headquartered life sciences instrumentation company that develops optical instruments and consumables for the label-free analysis of molecular interactions, serving pharmaceutical, biotechnology, and academic research customers in drug discovery and life sciences R&D. Its core product, the Creoptix WAVE, is a next-generation bioanalytical instrument built on proprietary Grating-Coupled Interferometry (GCI) biosensor technology, paired with custom no-clog WAVEchip microfluidic sensor chips and the WAVEcontrol software suite (including Direct Kinetics and waveRAPID modules). The system is designed to deliver high sensitivity and resolution for real-time kinetic characterization of fragments, small molecules, peptides, membrane proteins, and biologics, including analysis in crude reaction mixtures and undiluted biofluids such as serum and plasma — a workflow advantage versus traditional SPR-based platforms.

The company's revenue model combines capital instrument sales with recurring WAVEchip consumables, software licenses, and professional services such as training and technical support. Creoptix operates an enterprise B2B go-to-market, historically direct and now executed primarily through Malvern Panalytical's global field-sales organization, regional offices (including Boston for North America), and the Mystore e-commerce platform. Since the January 2022 integration into Malvern Panalytical — itself a subsidiary of UK-listed Spectris plc — Creoptix has functioned as a brand within a larger analytical instrumentation portfolio, targeting pharmaceutical and biotechnology firms as the primary vertical and academic research institutions as a secondary segment.

Short descriptiontext

Creoptix is a Switzerland-based brand of Malvern Panalytical that develops the WAVE bioanalytical instrument and microfluidic consumables, using proprietary GCI technology for label-free molecular interaction analysis in drug discovery and life sciences R&D, serving pharmaceutical, biotech, and academic customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWadenswil, Switzerland
HQ citystring
Wadenswil
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
label-free analysis, bioanalytical instruments, molecular interaction analysis, optical biosensors, drug discovery tools
Industry1 code
PRIMARYHLAGAIAB
Mass Spectrometry & Spectroscopy Instruments
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Optical Instruments & Lenses3827
Product category
Bioanalytical Instruments
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Bioanalytical Instruments (Hardware)
TypeHardware Sales
Description

Sale of the Creoptix WAVE next-generation bioanalytical instrument system for molecular interaction analysis in drug discovery and life sciences research.

malvernpanalytical.com
2Sensor Chips and Consumables
TypeHardware Sales
Description

WAVEchip microfluidic sensor chips designed for specific analytical needs, providing recurring consumables revenue.

malvernpanalytical.com
3Software Licenses and Support
TypeOne Time License
Description

Software products including WAVEcontrol, Direct Kinetics, and waveRAPID with associated support services.

malvernpanalytical.com
4Professional Services
TypeProfessional Services
Description

Product support, training, and technical services for instrument installation and operation.

malvernpanalytical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1WAVEsystem
Description

Next-generation bioanalytical instrument system for molecular interaction analysis

malvernpanalytical.com
+4 more records
Core offering1 text field

Creoptix develops and sells the WAVE next-generation bioanalytical instrument, a label-free optical biosensor system based on proprietary Grating-Coupled Interferometry (GCI) for real-time molecular interaction analysis in drug discovery and life sciences research. The company also supplies WAVEchip microfluidic sensor chips as consumables and WAVEcontrol software for instrument control and data analysis, serving pharmaceutical, biotechnology, and academic research customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Creoptix is a Malvern Panalytical brand offering a unified product portfolio centered on the Creoptix WAVE platform — a next-generation bioanalytical instrument for molecular interaction analysis. The WAVEsystem serves as the core product, supported by WAVEchip (microfluidic sensor chips), WAVEcontrol software (instrument control and data analysis), Direct Kinetics (1-click kinetic evaluation), and waveRAPID (kinetic measurement technique). Proprietary technologies include Grating-Coupled Interferometry (GCI) for high-sensitivity biophysical characterization and advanced microfluidics for sample compatibility. The portfolio is designed for drug discovery and life sciences research, enabling real-time analysis of molecular interactions across fragment, small molecule, peptide, membrane protein, and biologic targets in complex matrices.

Product and service3 records
1WAVEsystem (Creoptix WAVE)
CategoryBioanalytical Instruments
Description

Next-generation bioanalytical instrument for label-free, real-time molecular interaction analysis based on proprietary Grating-Coupled Interferometry (GCI) biosensor and WAVE microfluidic technology. Provides exceptionally high sensitivity and resolution to study real-time biological interactions involving fragments, small molecules, peptides, membrane proteins, biologics and other molecules in crude reaction mixtures and biofluids including undiluted serum and plasma. Sold to pharmaceutical, biotechnology, and academic life sciences customers.

2WAVEchip microfluidic sensor chips
CategoryConsumables
Description

No-clog microfluidic sensor chips designed for various analytical needs and use cases on the Creoptix WAVE instrument. Sold as recurring consumables that generate ongoing revenue tied to the installed base of WAVE instruments.

3WAVEcontrol software
CategorySoftware
Description

Fast, intuitive, automated software for instrument control and data analysis of the Creoptix WAVE system. Provides automated workflows and one-click evaluation capabilities supporting label-free molecular interaction analysis, kinetics evaluation, and binding affinity measurements for pharmaceutical, biotechnology, and academic research users.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cytiva's Biacore line is the dominant Surface Plasmon Resonance (SPR) platform for label-free molecular interaction analysis in drug discovery, directly competing with the Creoptix WAVE in pharma, biotech, and academic labs.

TypeDirect peer
Description

Sartorius's ForteBio Octet platform uses Bio-Layer Interferometry (BLI) for label-free kinetic and binding analysis, making it one of the closest direct competitors to Creoptix WAVE in biotherapeutic characterization and drug discovery workflows.

TypeBroad incumbent
Description

Molecular Devices supplies a broad portfolio of bioanalytical and screening instruments used in drug discovery, including label-free detection and kinetic analysis systems that overlap with Creoptix's molecular interaction analysis offering.

TypeBroad incumbent
Description

Bruker is a large analytical-instruments provider with life-science and biophysical characterization products that compete in adjacent segments to Creoptix, including mass spectrometry and surface-analysis tools used in pharma R&D.

TypeBroad incumbent
Description

Waters is a global analytical-instruments leader and was an investor in Creoptix's 2019 Series C; its chromatography and mass-spec portfolio overlaps with the broader bioanalytical workflow where the WAVE is positioned.

TypeBroad incumbent
Description

Agilent offers a broad portfolio of analytical instruments, separation systems, and life-science tools used by pharma and biotech customers, competing for budget allocations within the same customer labs as Creoptix.

TypeBroad incumbent
Description

Revvity operates life-sciences and analytical-instruments businesses spanning detection, imaging, and bioanalytical workflows used in drug discovery and biologics development, broadly comparable to Creoptix's customer environment.

TypeDirect peer
Description

Nanion provides label-free and microfluidic platforms for molecular interaction and electrophysiology analysis, overlapping with Creoptix WAVE in biophysical characterization for drug discovery and membrane-protein research.

TypeEmerging player
Description

Nicoya offers OpenSPR, a lower-cost, accessible SPR-based instrument for molecular interaction analysis, positioning it as an emerging alternative to Creoptix WAVE in academic and biotech labs.

TypeEmerging player
Description

BioNavis provides multi-parametric surface plasmon resonance (MP-SPR) instruments for label-free interaction and kinetics analysis, representing an emerging alternative technology in the same molecular interaction analysis niche as Creoptix.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Creoptix

Bioanalytical Instrumentscreoptix.com

Creoptix is a Switzerland-based brand of Malvern Panalytical that develops the WAVE bioanalytical instrument and microfluidic consumables, using proprietary GCI technology for label-free molecular interaction analysis in drug discovery and life sciences R&D, serving pharmaceutical, biotech, and academic customers.

What Creoptix does

Creoptix is a Swiss-headquartered life sciences instrumentation company that develops optical instruments and consumables for the label-free analysis of molecular interactions, serving pharmaceutical, biotechnology, and academic research customers in drug discovery and life sciences R&D. Its core product, the Creoptix WAVE, is a next-generation bioanalytical instrument built on proprietary Grating-Coupled Interferometry (GCI) biosensor technology, paired with custom no-clog WAVEchip microfluidic sensor chips and the WAVEcontrol software suite (including Direct Kinetics and waveRAPID modules). The system is designed to deliver high sensitivity and resolution for real-time kinetic characterization of fragments, small molecules, peptides, membrane proteins, and biologics, including analysis in crude reaction mixtures and undiluted biofluids such as serum and plasma — a workflow advantage versus traditional SPR-based platforms.

The company's revenue model combines capital instrument sales with recurring WAVEchip consumables, software licenses, and professional services such as training and technical support. Creoptix operates an enterprise B2B go-to-market, historically direct and now executed primarily through Malvern Panalytical's global field-sales organization, regional offices (including Boston for North America), and the Mystore e-commerce platform. Since the January 2022 integration into Malvern Panalytical — itself a subsidiary of UK-listed Spectris plc — Creoptix has functioned as a brand within a larger analytical instrumentation portfolio, targeting pharmaceutical and biotechnology firms as the primary vertical and academic research institutions as a secondary segment.

Creoptix firmographics

Firmographics
Name
Creoptix
Legal name
Creoptix (Malvern Panalytical brand)
Website
https://creoptix.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Creoptix is a Switzerland-based brand of Malvern Panalytical that develops the WAVE bioanalytical instrument and microfluidic consumables, using proprietary GCI technology for label-free molecular interaction analysis in drug discovery and life sciences R&D, serving pharmaceutical, biotech, and academic customers.
Ownership category
akta.pro rank

Creoptix industry classification

Industry
Product category
Bioanalytical Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAGAIAB
Mass Spectrometry & Spectroscopy Instruments

Keywords

  • Label-free analysis
  • Bioanalytical instruments
  • Molecular interaction analysis
  • Optical biosensors
  • Drug discovery tools

Where Creoptix is headquartered

Location

Headquarters

HQ city
Wadenswil
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Creoptix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Bioanalytical Instruments (Hardware): Sale of the Creoptix WAVE next-generation bioanalytical instrument system for molecular interaction analysis in drug discovery and life sciences research.
  2. Sensor Chips and Consumables: WAVEchip microfluidic sensor chips designed for specific analytical needs, providing recurring consumables revenue.
  3. Software Licenses and Support: Software products including WAVEcontrol, Direct Kinetics, and waveRAPID with associated support services.
  4. Professional Services: Product support, training, and technical services for instrument installation and operation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Creoptix product offering

Product offering

Core offering

Creoptix develops and sells the WAVE next-generation bioanalytical instrument, a label-free optical biosensor system based on proprietary Grating-Coupled Interferometry (GCI) for real-time molecular interaction analysis in drug discovery and life sciences research. The company also supplies WAVEchip microfluidic sensor chips as consumables and WAVEcontrol software for instrument control and data analysis, serving pharmaceutical, biotechnology, and academic research customers.

Product overview

Creoptix is a Malvern Panalytical brand offering a unified product portfolio centered on the Creoptix WAVE platform — a next-generation bioanalytical instrument for molecular interaction analysis. The WAVEsystem serves as the core product, supported by WAVEchip (microfluidic sensor chips), WAVEcontrol software (instrument control and data analysis), Direct Kinetics (1-click kinetic evaluation), and waveRAPID (kinetic measurement technique). Proprietary technologies include Grating-Coupled Interferometry (GCI) for high-sensitivity biophysical characterization and advanced microfluidics for sample compatibility. The portfolio is designed for drug discovery and life sciences research, enabling real-time analysis of molecular interactions across fragment, small molecule, peptide, membrane protein, and biologic targets in complex matrices.

Differentiator

Problem solved

Functional benefit

Brands

  • WAVEsystem: Next-generation bioanalytical instrument system for molecular interaction analysis
  • WAVEchip
  • WAVEcontrol
  • waveRAPID
  • Direct Kinetics

Products and services

  • WAVEsystem (Creoptix WAVE) Next-generation bioanalytical instrument for label-free, real-time molecular interaction analysis based on proprietary Grating-Coupled Interferometry (GCI) biosensor and WAVE microfluidic technology. Provides exceptionally high sensitivity and resolution to study real-time biological interactions involving fragments, small molecules, peptides, membrane proteins, biologics and other molecules in crude reaction mixtures and biofluids including undiluted serum and plasma. Sold to pharmaceutical, biotechnology, and academic life sciences customers.
  • WAVEchip microfluidic sensor chips No-clog microfluidic sensor chips designed for various analytical needs and use cases on the Creoptix WAVE instrument. Sold as recurring consumables that generate ongoing revenue tied to the installed base of WAVE instruments.
  • WAVEcontrol software Fast, intuitive, automated software for instrument control and data analysis of the Creoptix WAVE system. Provides automated workflows and one-click evaluation capabilities supporting label-free molecular interaction analysis, kinetics evaluation, and binding affinity measurements for pharmaceutical, biotechnology, and academic research users.

Companies that use Creoptix

Customer profile

Segments2 records

Ideal customer profiles2 records

Creoptix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Creoptix partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Creoptix competitors and assessment

Company assessment

Direct peers

  • Cytiva (Biacore): Cytiva's Biacore line is the dominant Surface Plasmon Resonance (SPR) platform for label-free molecular interaction analysis in drug discovery, directly competing with the Creoptix WAVE in pharma, biotech, and academic labs.
  • Sartorius (ForteBio / Octet): Sartorius's ForteBio Octet platform uses Bio-Layer Interferometry (BLI) for label-free kinetic and binding analysis, making it one of the closest direct competitors to Creoptix WAVE in biotherapeutic characterization and drug discovery workflows.
  • Nanion Technologies: Nanion provides label-free and microfluidic platforms for molecular interaction and electrophysiology analysis, overlapping with Creoptix WAVE in biophysical characterization for drug discovery and membrane-protein research.

Broad incumbents

  • Molecular Devices (Danaher): Molecular Devices supplies a broad portfolio of bioanalytical and screening instruments used in drug discovery, including label-free detection and kinetic analysis systems that overlap with Creoptix's molecular interaction analysis offering.
  • Bruker: Bruker is a large analytical-instruments provider with life-science and biophysical characterization products that compete in adjacent segments to Creoptix, including mass spectrometry and surface-analysis tools used in pharma R&D.
  • Waters Corporation: Waters is a global analytical-instruments leader and was an investor in Creoptix's 2019 Series C; its chromatography and mass-spec portfolio overlaps with the broader bioanalytical workflow where the WAVE is positioned.
  • Agilent Technologies: Agilent offers a broad portfolio of analytical instruments, separation systems, and life-science tools used by pharma and biotech customers, competing for budget allocations within the same customer labs as Creoptix.
  • Revvity (formerly PerkinElmer): Revvity operates life-sciences and analytical-instruments businesses spanning detection, imaging, and bioanalytical workflows used in drug discovery and biologics development, broadly comparable to Creoptix's customer environment.

Emerging players

  • Nicoya Lifesciences: Nicoya offers OpenSPR, a lower-cost, accessible SPR-based instrument for molecular interaction analysis, positioning it as an emerging alternative to Creoptix WAVE in academic and biotech labs.
  • BioNavis: BioNavis provides multi-parametric surface plasmon resonance (MP-SPR) instruments for label-free interaction and kinetics analysis, representing an emerging alternative technology in the same molecular interaction analysis niche as Creoptix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Creoptix social profiles

Digital presence

Creoptix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Creoptix leadership team

Management profile

Number of profiles

Profiles3 records

Creoptix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Creoptix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Creoptix

What does Creoptix do?

Creoptix develops and sells the WAVE next-generation bioanalytical instrument, a label-free optical biosensor system based on proprietary Grating-Coupled Interferometry (GCI) for real-time molecular interaction analysis in drug discovery and life sciences research. The company also supplies WAVEchip microfluidic sensor chips as consumables and WAVEcontrol software for instrument control and data analysis, serving pharmaceutical, biotechnology, and academic research customers.

Is Creoptix a public or private company?

Creoptix is a private company. It is classified as corporate owned and is currently operating.

When was Creoptix founded?

Creoptix was founded in 2022. It employs 11 to 50 people.

Where is Creoptix based?

Creoptix is headquartered in Wadenswil, Switzerland, in the Europe region.

How does Creoptix make money?

Four revenue lines are on record. Bioanalytical Instruments (Hardware) is the primary driver. The others are sensor Chips and Consumables, software Licenses and Support and professional Services.

Who are Creoptix's main competitors?

Direct peers on record are Cytiva (Biacore), Sartorius (ForteBio / Octet) and Nanion Technologies. Broad incumbents are Molecular Devices (Danaher), Bruker, Waters Corporation, Agilent Technologies and Revvity (formerly PerkinElmer). Emerging players are Nicoya Lifesciences and BioNavis.

Does Creoptix have an API?

No public API is recorded for Creoptix.

What industry is Creoptix in?

Creoptix's product category is Bioanalytical Instruments. Its primary akta.pro industry code is HLAGAIAB, Mass Spectrometry & Spectroscopy Instruments. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
punkt4Malvern Panalytical kauft CreoptixBritish company Malvern Panalytical has acquired the Swiss startup Creoptix, which specializes in analytical laboratory equipment for life sciences and pharmaceutical research. This acquisition allows Malvern Panalytical to expand its capabilities in supporting pharmaceutical development, particularly regarding small molecules. Creoptix, founded in 2009, previously received investment from Waters Corporation and Swisscanto.news.cision.comCreoptix launches waveRAPID[®] – a new and faster way of measuring kinetics to accelerate drug discoveryCreoptix launched waveRAPID, a label-free kinetic measurement method that is six times faster than traditional methods. The company's WAVEsystem uses Grating-Coupled Interferometry to study molecular interactions in real time, aiming to accelerate drug discovery. Creoptix will host a virtual webinar on 2 February 2021 to explain the method.AiThorityCreoptix and Oneservice Partner for WavesystemAfter-Sales SupportCreoptix signed an agreement with oneservice to provide after-sales support for its WAVEsystem biosensor in Europe and the US. The label-free biosensor uses Grating-Coupled Interferometry technology, offering sensitivity superior to Surface Plasmon Resonance. The partnership aims to support existing and future customers in both regions.news.cision.com2bind and Creoptix sign technology-service partnershipCreoptix and 2bind signed a technology-service partnership to offer label-free biosensing tools for drug discovery. The collaboration integrates Creoptix's WAVEsystem, which uses Grating-Coupled Interferometry, into 2bind's service portfolio. Creoptix will use 2bind as a certified service provider and beta-tester for future developments.news.cision.comCreoptix Appoints Line Stigen Raquet as Chief Executive OfficerCreoptix appointed Line Stigen Raquet as CEO effective January 2020, replacing Matyas Vegh after seven years. She comes from Mettler Toledo, where she was VP of Business Development Life Sciences, and previously led QIAGEN's APAC marketing team. Creoptix aims to accelerate commercial growth with its WAVE systems.AgFunderNewsMicrofluidics mastery earns Switzerland’s Creoptix $8m Series CSwiss biotech Creoptix raised CHF 8 million in a Series C round led by Swisscanto Invest, with Waters Corporation joining. The funds will support commercial expansion in Europe and the US, bringing total funding to over CHF 15 million since 2013.PrivateequitywireCreoptix raises CHF8m Series C financing round - Private Equity WireCreoptix AG raised CHF8 million in a Series C round led by Swisscanto Invest and Waters Corporation. The company has now raised over CHF15 million since 2013, and the funds will support commercial expansion in Europe and the US.startupticker.chCreoptix attracts Waters as corporate investorCreoptix AG secured new investment from Waters Corporation, with Waters joining as corporate investor and Geoff Gerhardt joining the board. Creoptix's WAVE systems use waveguide technology for real-time molecular interaction studies. The partnership aims to expand Creoptix's market presence and support biopharmaceutical development.startupticker.chLeadXpro AG relies on Creoptix’s technologyLeadXpro AG, a lead discovery start-up, selected Creoptix's WAVE technology for its membrane protein drug discovery work. The company will use the WAVEdelta system to analyze kinetics and affinity in real-time, combining it with its expertise in assay development and structure-based methods.NewswireleadXpro to Work With Creoptix Wave Technology for Their Membrane Protein Drug Discovery ProjectsleadXpro selected Creoptix's WAVE technology for its membrane protein drug discovery projects. The WAVEdelta system provides real-time label-free molecular interaction analysis with high sensitivity and broad sample compatibility. leadXpro will combine it with its expertise in assay development and high-throughput screening.